PlainPill

Retatrutide

Also known as LY3437943

The short answer. Most people who report on Retatrutide say it helped (76% of 327). It is most often used for weight loss: 92% of 228 reports say that improved. There is a moderate body of research — 22 meta-analyses and 6 trials. The most common complaint is nausea. It is not an approved supplement and carries real risks.

What users report
76%helped327 reports · high confidence
248 helped69 mixed9 didn't help

From 460 mentions in total — the rest didn't say how it went and aren't counted.

Clinical research
BModerate research base
22
meta-analyses
6
RCTs
192
papers
High-risk compound. Peptides are not approved as supplements, carry serious and sometimes irreversible risks, are banned in competitive sport and may be restricted where you live. Nothing here is a recommendation to use it.

What Retatrutide does, according to users

Of the people who reported each effect, the share who said it got better.

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

BModerate research base

At least one meta-analysis, or 5+ randomized controlled trials. The grade measures how much human research exists — read the conclusions below for what it found. 22 meta-analyses on PubMed ↗ · 6 randomized trials ↗

Pharmacol Rev · 2025 · Meta-analysis / systematic review
Emerging pharmacotherapies for obesity: A systematic review

Conclusion: This systematic review identifies the state and mechanism of action of emerging pharmacotherapies undergoing or having completed phase 2 and phase 3 clinical trials. The information provided herein furthers the understanding of obesity management, implying direct clinical implications and stimulating research initiatives.

PubMed 39952695 ↗
Endocrinol Diabetes Metab · 2025 · Meta-analysis / systematic review
Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

Conclusion: GLP-1 RAs carry a slightly increased risk of pancreatitis, which is not significant when stratified by background medication use. Overall risk for pancreatic cancer was not observed, but a slight association was found when stratified with background medications. However, this difference is likely minimal, given the numerous studies excluded from the meta-analysis where both treatment arms had zero events.

PubMed 40988099 ↗
Metabolism · 2024 · Meta-analysis / systematic review
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials

Conclusion: Retatrutide (both doses) and tirzepatide exhibited superior efficacy compared to other GLP-1 receptor agonists and polyagonists in reducing body weight and waist circumference. Patients without T2DM, those with a high BMI, and individuals undergoing longer treatment cycles demonstrated significantly greater weight loss and reductions in waist circumference. Dual or triple receptor agonists (GLP-1 plus glucose-dependent insulinotropic polypeptide and/or Glucagon receptor) are more effective for weight loss than GLP-1 receptor agonists.

PubMed 39305981 ↗
Registered clinical trials

33 human trials on ClinicalTrials.gov test Retatrutide — 21 completed, 2 recruiting now. See all on ClinicalTrials.gov ↗

What government agencies say

Official records from US, Canadian and EU regulators, each linked to its source.

US government research funding (NIH)

NIH has funded 1 research project with Retatrutide in the title, $372,400 in total (2025–2025). NIH RePORTER ↗

Dosage people report

We don't list doses for unapproved research compounds. Dosing should only come from a doctor or pharmacist.

Reported side effects

How often each side effect came up across all reports.

nausea ×19fatigue ×18stomach issues ×18insomnia ×15increased heart ×14constipation ×7appetite suppression ×6muscle loss ×1

What users say

First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.

“Drastically reduced appetite: At 5mg, I experienced near-total suppression of hunger and cravings. Steady, effortless fat loss: I didn't have to track macros obsessively or do extreme cardio.”
HelpedRead the discussion ↗
“I’ve tried Reta and it melted fat away at 1mg - I really disliked the increased heart rate (and it was only 8bpm) and the nuking of my HRV.”
MixedRead the discussion ↗
“Once I started Reta at 2mg in January, it completely changed my mindset.”
HelpedRead the discussion ↗
“I lost 115 lbs in the last year (260 → 145)...retatrutide seemed to finally address my insulin resistance.”
HelpedRead the discussion ↗
Read more Retatrutide reviews →
Top discussions (5)

Retatrutide compared

Other options for weight loss

Sources

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate